180 related articles for article (PubMed ID: 22875628)
21. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
[TBL] [Abstract][Full Text] [Related]
22. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
23. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
24. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
25. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
Mullally A
Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
[TBL] [Abstract][Full Text] [Related]
26. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
28. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
[TBL] [Abstract][Full Text] [Related]
29. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
30. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
31. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
[TBL] [Abstract][Full Text] [Related]
32. The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion.
Mayumi A; Tomii T; Kanayama T; Mikami T; Tanaka K; Ueno H; Yoshida H; Kato I; Kawamura M; Nakahata T; Takita J; Hosoi H; Imamura T
Cancer Gene Ther; 2022 Dec; 29(12):1930-1938. PubMed ID: 35879405
[TBL] [Abstract][Full Text] [Related]
33. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
[TBL] [Abstract][Full Text] [Related]
34. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.
Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST; Traina F
Oncotarget; 2015 Oct; 6(30):29573-84. PubMed ID: 26356819
[TBL] [Abstract][Full Text] [Related]
35. AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I; Huang Z; Wen Q; Stankiewicz MJ; Gilles L; Goldenson B; Schultz R; Diebold L; Gurbuxani S; Finke CM; Lasho TL; Koppikar P; Pardanani A; Stein B; Altman JK; Levine RL; Tefferi A; Crispino JD
Leukemia; 2013 Sep; 27(9):1882-90. PubMed ID: 23748344
[TBL] [Abstract][Full Text] [Related]
36. [Small molecular compounds for BCR/ABL-negative myeloproliferative neoplasms].
Nagai T
Nihon Rinsho; 2014 Jun; 72(6):1073-8. PubMed ID: 25016807
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
38. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
39. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms.
Petiti J; Lo Iacono M; Rosso V; Andreani G; Jovanovski A; Podestà M; Lame D; Gobbi M; Fava C; Saglio G; Frassoni F; Cilloni D
J Cell Mol Med; 2020 Sep; 24(18):10978-10986. PubMed ID: 32790151
[TBL] [Abstract][Full Text] [Related]
40. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
